1、Q1 2023 ResultsConference call and webcast for investors and analysts27 April 2023 Forward-looking statements2In order,among other things,to utilise the safe harbour provisions of the US Private Securities Litigation Reform Act of 1995,AstraZeneca(hereafter the Group)provides the following cautionar

2、y statement:This document contains certain forward-looking statements with respect to the operations,performance and financial condition of the Group,including,among other things,statements about expected revenues,margins,earnings per share or other financial or other measures.Although the Group bel

3、ieves its expectations are based on reasonable assumptions,any forward-looking statements,by their very nature,involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted.The forward-looking statements

4、reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements.The Group identifies the forward-looking statements by using the words anticipates,believes,expects,intends and similar expression

5、s in such statements.Important factors that could cause actual results to differ materially from those contained in forward-looking statements,certain of which are beyond the Groups control,include,among other things:the risk of failure to meet regulatory or ethical requirements for medicine develop

6、ment or approval;the risk of failures or delays in the quality or execution of the Groups commercial strategies;the risk of pricing,affordability,access and competitive pressures;the risk of failure to maintain supply of compliant,quality medicines;the risk of illegal trade in the Groups medicines;t